期刊文献+

西洛他唑与氯吡格雷对ACS患者抗炎作用研究 被引量:2

下载PDF
导出
摘要 目的探讨抗血小板药西洛他唑、氯吡格雷对急性冠脉综合征(ACS)患者斑块稳定性和炎症抑制的作用机制,以及与他汀类药物的协同作用。方法入选82例ACS患者随机分成A组(常规用药+阿托伐他汀)、B组(氯吡格雷常规用药)和C组(西洛他唑+常规用药),观察治疗3周后血脂、白细胞(WBC)计数和高敏C反应蛋白(hs-CRP)、肿瘤坏死因子-a(TNF-a)、白介素-1β(IL-1β)水平变化、临床疗效和不良反应。结果 3组在治疗后WBC计数、三酰甘油(TG)、胆固醇(TC)、低密度脂蛋白(LDL-C)较治疗前均下降(P<0.05),下降幅度组间比较无统计学意义;3组治疗后高密度脂蛋白(HDL-C)上升(P<0.05);3组治疗后TNF-a、IL-1β和hs-CRP水平均下降(P<0.05),氯吡格雷、西洛他唑两组下降幅度均大于常规用药(P<0.05)。治疗前后TNF-a、IL-1β变化值与HDL-C变化值呈负相关(r=-0.38,P=0.04;r=-0.39,P=0.03)。结论予ACS患者阿托伐他汀联用西洛他唑或氯吡格雷较单用阿托伐他汀均可进一步降低致炎因子水平,抑制血小板活化。
出处 《中西医结合心脑血管病杂志》 2013年第1期101-103,共3页 Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease
  • 相关文献

参考文献17

  • 1Cyrus T,Sung S,Zhao L. Effect of low-dose aspirin on vascular inflammation,plaque stability,and atherogenesis in low-density lipoprotein receptor deficient mice[J].Circulation,2002,(10):1282-1287.
  • 2Libby P,Ridker PM,Maseri A. Inflammation and atherosclerosis[J].Circulation,2002,(09):1135-1143.
  • 3李艳 ,黄从新 .重要炎性因子在冠心病病理过程中的作用[J].微循环学杂志,2004,14(1):47-49. 被引量:16
  • 4Ferreios ER,Boissonnet CP,Pizarro R. Independent prognostic value of elevated C-reactive protein in unstable angina[J].Circulation,1999,(19):1958-1963.
  • 5Prediman K,Shah MD. Plaque disruption and thrombosis:Potential role of inflammation and infection[J].Cardiology in Review,2000,(03):32-39.
  • 6Muir KW,Weir CJ,Alwan W. C-reactive protein and outcome after ischemic stroke[J].Stroke,1999,(05):981-985.
  • 7Rosenson RS,Koenig W. High-sensitivity C-reactive protein and cardiovascular risk in patients with coronary heart disease[J].Current Opinion in Cardiology,2002,(04):325-331.
  • 8Huo Y,Schober A,Forlow SB. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E[J].Nature Medicine,2003,(01):61-67.doi:10.1038/nm810.
  • 9顾晴,陈纪林,阮英茆.阿司匹林、氯吡格雷及合用对兔动脉粥样硬化病变进展的抑制作用[J].中国医学科学院学报,2005,27(1):87-91. 被引量:46
  • 10唐熠达,陈纪林,阮英茆,徐新林,王清峙,司文学,张连庄,杨跃进,高润霖,陈在嘉.不同剂量阿司匹林对兔动脉粥样硬化斑块进展的抑制作用[J].中华心血管病杂志,2003,31(8):609-612. 被引量:41

二级参考文献63

  • 1[1]Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med, 1999, 340:115~126.
  • 2[2]Mehta JL, Saldeen TGP, Rand K. Interactive role of infection, inflammation and traditional risk factors in atherosclerosis and coronary artery disease. J AM Coll Cardiol, 1998, 31:1 217~1 225.
  • 3[3]Schreyer SA, Vick CM,LeBoeuf RC. Loss of lymphotoxin-α but not tumor necrosis factor-α reduces atherosclerosis in mice. J Biol Chem, 2002, 277:12 364~12 368.
  • 4[4]Libby P, Warner SJ, Friedman GB. Interleukin-1: a mitogen for human vascular smooth muscle cells that induces the release of growth-inhibitory prostanoids. J Clin Invest,1998, 81:487~498.
  • 5[5]Kastrati A, Koch W, Berger PB, et al. Protective role against restenosis from an interleukin-1receptor antagonist gene polymorphism in patients treated with coronary stenting. JACC, 2000, 36:2 168~2 173.
  • 6[6]Dewberry R, Holden H, Crossman D, et al. Interleukin-1 receptor antagonist expression in human endothelial cell and atherosclerosis. Arterioscler Thromb Vasc Biol, 2000, 20:2 394~2 400.
  • 7[7]Galea J, Armstrong JA, Gadsdon PA, et al. Interleukin-1β in coronary arteries of patients with ischemic heart disease. Arterioscler Thromb Vasc Biol, 1996, 16:1 000~1 006.
  • 8[8]Yudkin JS, Stehouwer CDA, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects-associations with obesity, insulin resistance and endothelial dysfunction. A potential role for cytokines originating from adipose tissue? Art Thromb Vasc Biol,1999,19:972~978.
  • 9[9]Romano M, Sironi M, Toniatti C, et al. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity,1997,6:1–20.
  • 10[10]Davies MJ. The composition of coronary artery plaques. New Engl J med, 1997, 336:1 312~1 314.

共引文献102

同被引文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部